Aldeyra Therapeutics, Inc.

Stage 4 · Declining · week 11

As of Oct 22, 2026, Aldeyra Therapeutics is in Stage 4, the downtrend phase, now in week 11 (since Aug 10, 2026). It closed at $0.65, 88.5% below its 52-week high and below its 200-day average, which is falling.

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. More about the company

$0.65

-3.82% today

$38.9M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ALDX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 20w

S2 13w

S3 14w

S4 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 1w → S4 20w → S1 11w → S4 2w → S1 8w → S2 3w → S3 7w → S2 13w → S3 12w → S2 9w → S3 2w → S4 10w → S1 6w → S2 11w → S3 14w → S2 5w → S3 1w → S4 14w → S1 6w → S4 11w current

Total tracked: 165 weeks across 20 stage runs.

ALDX among Biotechnology499th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…499	ALDXAldeyra Therapeutics, Inc.	Stage 4 · wk 11	8	−52.2%

vs 52W High

-88.5%

$0.65 lo$5.62 hi

88.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 11

1w13w26w

Week 11, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-73.0%

200 DMA: $2.38 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.57x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-52.2%

-57.6%

-59.7%

YTD

-86.2%

-88.3%

Scan Membership

Breakout Watch

Latest: 2025-02-07

10 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 11 · Vol 0.57x

2026-10-21S4

Wk 11 · Vol 0.46x

2026-10-20S4

Wk 11 · Vol 1.33x

2026-10-19S4

Wk 10 · Vol 0.69x

2026-10-16S4

Wk 10 · Vol 1.48x

2026-10-15S4

Wk 10 · Vol 1.02x

2026-10-14S4

Wk 10 · Vol 1.31x

2026-10-13S4

Wk 10 · Vol 1.23x

2026-10-12S4

Wk 9 · Vol 1.14x

2026-10-09S4

Wk 9 · Vol 0.60x

2026-10-08S4

Wk 9 · Vol 1.01x

2026-10-07S4

Wk 9 · Vol 1.11x

Moving averages & range

50 DMA

$1.25

200 DMA

$2.38

52W High

$5.62

52W Low

$0.65

5D Low

$0.65

Resistance levels (recent highs)

20d High

$1.32

60d High

$1.60

120d High

$2.43

250d High

$5.62

Next resistance

+104.7%

to 20d High

ROE

-49.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.0

Aldeyra Therapeutics: quick answers

What stage is Aldeyra Therapeutics in?

As of Oct 22, 2026, Aldeyra Therapeutics (ALDX) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 10, 2026 and is in week 11. What the four stages mean

Is Aldeyra Therapeutics in an uptrend?

No. Aldeyra Therapeutics is in a Stage 4 downtrend. It trades 73.0% below its 200-day average, which is falling.

How far is Aldeyra Therapeutics from its 52-week high?

Aldeyra Therapeutics closed at $0.65 on Oct 22, 2026, 88.5% below its 52-week high of $5.62. Its 52-week low is $0.65.

How has Aldeyra Therapeutics performed over the past year?

As of Oct 22, 2026, Aldeyra Therapeutics is down 88.3% over the past year and down 86.2% so far in 2026.

Which sector and industry is Aldeyra Therapeutics in?

Aldeyra Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.